earnings

SmileDirectClub, Inc. (SDC) reported a wider loss in the first quarter of 2020 due to higher costs and expenses. However, the top-line increased by 11% year-over-year driven by an increase in unique aligner shipments and higher average aligner gross sales price. Take a look at the visual...

On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks...

Mylan N.V. (MYL) reported its financial results for the quarter ended March 31, 2020, on Monday before the market opens. The company reaffirmed its financial guidance for the full-year 2020. The results were driven by overall volume growth, which was favorably impacted by increased customer...

Regeneron Pharmaceuticals, Inc. (REGN) reported a 36% jump in earnings for the first quarter of 2020 helped by higher revenue. The results exceeded analysts’ expectations. The company is advancing REGN-COV2, a novel investigational antibody “cocktail” treatment designed to prevent and treat the...

Pharmaceutical company Eli Lilly (LLY) reported first-quarter 2020 revenue of $5.86 billion, up 15% year-over-year. Amid COVID-19 pandemic, the company saw increased customer buying patterns and prescription trends which resulted in a revenue increase of approx. $250 million for the quarter...

Johnson & Johnson (JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced...

Merck surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in premarket hours on Tuesday. Worldwide sales rose 15% year-over-year to $12.4 billion, beating estimates of $11.6 billion. Excluding foreign exchange impacts, sales...

Eli Lilly surpassed earnings expectations for the third quarter of 2019 but revenues came in shy of estimates. Total revenue grew 3% year-over-year to $5.47 billion, but fell short of estimates of $5.5 billion. Revenues grew 4% excluding foreign currency impacts. Revenue growth was driven by an...

Abbott Laboratories’ third quarter 2019 earnings came in line with the market’s projections, while sales missed the expectations. The pharma company reported adjusted EPS of $0.84 on sales of $8.08 billion. Wall Street had forecasted Abbott to post earnings of $0.84 on sales of $8.11 billion...

Earnings of Johnson & Johnson increased and topped the Street view in Q3 helped by a 2% growth in sales. Encouraged by the positive outcome, the management revised up its full-year earnings and sales outlook. The company’s stock gained following the announcement. Read More

Biogen reported second-quarter earnings that surpassed Wall Street expectations. The company reported adjusted earnings of $9.15 per share, way ahead of the street projection of $7.53 per share. On a GAAP basis, earnings grew 88% to $7.85 per share. Revenue grew 8% to $3.62 billion, surpassing...

Novartis on Thursday surprised Wall Street by reporting a year-over-year increase in net earnings in Q2, helped by higher sales and a one-time divestment gain. The company said its earnings grew 14% to $1.34 per share, even as analysts were anticipating a decline. Riding on the strong sales of...

JNJ kicked off pharma earnings as it posted its first-quarter 2019 earnings on Tuesday, April 16, before the opening bell. Reported revenue for the quarter barely changed — inching just 0.1% higher — at $20 billion, while net earnings slipped 14% to $3.7 billion. On a diluted basis, earnings...

Worldwide sales increased 2.3% to of $7.77 billion. The results were benefited by the higher sales from Medical Devices and Diagnostics businesses. Sales from Medical Devices grew 6.7% year-over-year. In Electrophysiology, the 16.7% growth was led by strong performance in cardiac mapping and...

PG reported upbeat earnings results for the second quarter of 2019. Net profit soared 31% to $1.22 per diluted share in the quarter with US Tax Act impacting directly and via transitional charges. Core earnings rose 5% to $1.25 per share. Net sales was $17.4 billion, almost identical to a year...

JNJ saw sales inch 1% up to $20.4 billion in the fourth quarter of 2018. Operational sales results rose 3.3%. Domestic sales increased 1.5%, while international sales grew 0.4%. Adjusted earnings grew about 13% to $5.4 billion or $1.97 per diluted share While both Medical and Consumer segments...

Arrowhead Pharmaceuticals reports a loss of $0.12 per share in Q4 2018. Arrowhead doesn't report Q4 numbers in the quarterly press release. They only report Q4 numbers in the SEC filing.

What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/

Amgen earnings coverage With the recent launch of new products, sales improved 4% to $6.05 billion while profits jumped 17% touching $3.83 per share due to strong product sales. Free cash flow for the quarter came in at $1.9 billion, down 9.5% compared to last year due to increased tax outgo...

Earnings slipped more than 40% in the second quarter of FY2018 for Gilead. The company updated that John F. Milligan will step down as CEO and President. https://news.alphastreet.com/gilead-sciences-q2-2018-earnings-results/